Cervical Cancer in India

Cervical cancer is a malignant tumor arising from the cells of the cervix, which connects the lower part of the uterus to the vagina. In India, it ranks as the second most prevalent cancer among women, behind breast cancer, and accounts for nearly one-fifth of the global disease burden. Persistent infection with high-risk human papillomavirus (HPV) strains causes almost all cervical cancer cases. Although it is highly preventable through early vaccination and routine screening, late-stage diagnosis remains the primary cause of high mortality among Indian women.

Etiology and Risk Factors

Viral Etiology

The Human Papillomavirus (HPV) is a common sexually transmitted virus. More than 100 strains of HPV exist, but high-risk oncogenic types cause cervical dysplasia and invasive cancer. Types 16 and 18 are responsible for approximately 70% to 80% of cervical cancer cases in India. HPV-16 is the single most dominant genotype detected across various geographical regions in the country.

Associated Risk Factors

Several socio-demographic and lifestyle factors increase the risk of persistent HPV infection and its progression to malignancy:

• Early age at marriage or first sexual intercourse.

• High parity, defined as multiple pregnancies and childbirths.

• Poor personal and menstrual hygiene.

• Tobacco use and active or passive smoking.

• Immunosuppression, including HIV infection, which accelerates disease progression.

• Co-infections with other sexually transmitted diseases such as Chlamydia.

• Malnutrition and long-term use of oral contraceptives.

Epidemiological Profile in India

Disease Burden

India reports over 123,000 new cervical cancer cases and nearly 80,000 deaths annually. The age-standardized incidence rate in India is roughly 18 cases per 100,000 women. Over 60% of cases are diagnosed at locally advanced stages due to the absence of systematic population-based screening.

Geographical Disparities

Incidence rates vary across Indian states. The Papumpare district in Arunachal Pradesh records the highest incidence rate of cervical cancer in Asia at 27.7 per 100,000 women. Northeastern states generally exhibit higher disability-adjusted life years (DALYs) associated with cervical cancer compared to national averages.

Prevention Strategies: Vaccination and Screening

Primary Prevention: HPV Vaccination

Prophylactic vaccines target oncogenic HPV types to prevent infection. Vaccination is most effective when administered to adolescent girls aged 9 to 14 years before sexual exposure.

Cervavac: Indigenous Quadrivalent Vaccine

Cervavac is India’s first indigenous quadrivalent Human Papillomavirus vaccine, developed jointly by the Serum Institute of India and the Department of Biotechnology. It uses Virus-Like Particle (VLP) technology to generate immune responses without introducing live viral DNA. Cervavac targets HPV strains 6, 11, 16, and 18. Its low production cost makes large-scale public health drives economically viable compared to imported alternatives.

Secondary Prevention: Screening Methods

Screening identifies precancerous lesions before they transform into invasive carcinoma.

Government Initiatives and Healthcare Policies

National Programme for Prevention and Control of Non-Communicable Diseases (NPNCD)

The Ministry of Health and Family Welfare includes cervical cancer screening within the NPNCD framework (formerly NPCDCS). Operational guidelines recommend screening women aged 30 to 65 using Visual Inspection with Acetic Acid (VIA) at Primary Health Centres (PHCs) and Community Health Centres (CHCs) every five years.

National Technical Advisory Group on Immunization (NTAGI) Recommendations

NTAGI recommended incorporating the HPV vaccine into the Universal Immunization Programme (UIP). The planned strategy involves a multi-age cohort catch-up drive for girls aged 9 to 14 years, followed by routine administration at age 9.

State-Level Pilot Programs

Sikkim became the first Indian state to execute a state-wide HPV vaccination drive targeting girls aged 9 to 13 in schools, achieving over 95% coverage. Punjab also introduced district-level pilot programs to evaluate cost-effectiveness and logistics.

WHO 90-70-90 Targets for 2030

India is a signatory to the World Health Organization global strategy to eliminate cervical cancer as a public health problem. The strategy targets an incidence rate below 4 per 100,000 women through three key pillars:

• 90% of girls fully vaccinated with the HPV vaccine by age 15.

• 70% of women screened with a high-performance test by age 35 and again by age 45.

• 90% of women identified with cervical disease receiving treatment.

Challenges in Cervical Cancer Control

Low Screening Coverage

National Family Health Survey (NFHS-5) data indicates that less than 2% of Indian women have ever undergone cervical cancer screening. Lack of systematic invitation programs leads to reliance on opportunistic screening.

Socio-Cultural and Structural Barriers

Social stigma, embarrassment, lack of female healthcare providers in rural areas, and low public awareness hinder early care-seeking. Financial constraints, high out-of-pocket expenditure for tertiary cancer care, and inadequate laboratory networks slow down diagnostic confirmation and prompt treatment.

Key Facts for Quick Revision

• Cervical cancer is caused by persistent infection with high-risk Human Papillomavirus (HPV) strains, mainly HPV-16 and HPV-18.

• It is the second most common cancer among Indian women, accounting for nearly 22% of all cervical cancer deaths globally.

• Papumpare district in Arunachal Pradesh has the highest cervical cancer incidence rate in Asia.

• Cervavac is India’s first indigenous quadrivalent HPV vaccine, developed by the Serum Institute of India and the Department of Biotechnology.

• The primary screening method recommended by the Ministry of Health and Family Welfare at the primary health level is Visual Inspection with Acetic Acid (VIA).

• Universal Immunization Programme plans target girls aged 9–14 years for HPV vaccination.

• NFHS-5 data shows that fewer than 2% of Indian women have undergone cervical cancer screening.

• The WHO 90-70-90 elimination strategy aims to reduce the global incidence of cervical cancer below 4 cases per 100,000 women by 2030.